BRIEF—EMA to review Aradigm's appliation for Linhaliq

California’s Aradigm says the European Medicines Agency is to proceed with reviewing the firm’s application to market Linhaliq (ciprofloxacin liposomal) as a treatment for certain non-cystic fibrosis bronchiectasis (NCFBE) patients.

The announcement boosted shares in the company, months after the US Food and Drug Administration rejected Aradigm’s application for the drug in the same indication.

NCFBE is a severe, chronic and rare respiratory disease for which there are currently no treatments.